Your browser doesn't support javascript.
loading
Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab.
Hayashida, Michikata; Miura, Yuji; Noda, Taisho; Yamanaka, Taro; Tanaka, Naoto; Yasuoka, Shotaro; Oka, Suguru; Sakaguchi, Kazushige; Kinowaki, Keiichi; Urakami, Shinji.
Afiliação
  • Hayashida M; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Miura Y; Department of Medical Oncology Toranomon Hospital Tokyo Japan.
  • Noda T; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Yamanaka T; Department of Medical Oncology Toranomon Hospital Tokyo Japan.
  • Tanaka N; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Yasuoka S; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Oka S; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Sakaguchi K; Departments of Urology Toranomon Hospital Tokyo Japan.
  • Kinowaki K; Department of Pathology Toranomon Hospital Tokyo Japan.
  • Urakami S; Departments of Urology Toranomon Hospital Tokyo Japan.
IJU Case Rep ; 5(4): 268-272, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35795114
ABSTRACT

Introduction:

The effectiveness of nivolumab plus ipilimumab for metastatic renal cell carcinoma with inferior vena cava tumor thrombus remains unclear. Case presentation A 75-year-old male was diagnosed with metastatic renal cell carcinoma with inferior vena cava tumor thrombus and treated with nivolumab plus ipilimumab. The renal mass and thrombus regressed and all pulmonary nodules except for one lesion diminished. To avoid thrombotic complications, radical nephrectomy and thrombectomy were performed. No viable malignant cells were revealed histopathologically. Although nivolumab was continued after the surgical interventions, the remaining lesion did not change. Considering the discontinuation of nivolumab, metastasectomy was performed, and no viable malignant cells were revealed histopathologically. There has been no recurrence after the discontinuation.

Conclusion:

Nivolumab plus ipilimumab could have effectiveness for metastatic renal cell carcinoma with inferior vena cava tumor thrombus.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: IJU Case Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: IJU Case Rep Ano de publicação: 2022 Tipo de documento: Article